<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>A patient with <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) and a 47,XY,+21 karyotype at diagnosis, was documented to have a clonal chromosome 21 rearrangement, i(21q), four months before transformation to <z:hpo ids='HP_0005531'>acute biphenotypic leukemia</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>For 4 months after transformation, isochromosome 21 persisted while the patient was receiving treatment with <z:chebi fb="15" ids="10110">zidovudine</z:chebi> </plain></SENT>
<SENT sid="2" pm="."><plain><z:chebi fb="0" ids="28940">Vitamin D3</z:chebi> was added to <z:chebi fb="15" ids="10110">zidovudine</z:chebi> for an additional month, during which time the <z:mp ids='MP_0004027'>trisomy</z:mp> 21 clone reappeared as the predominant cell population </plain></SENT>
<SENT sid="3" pm="."><plain>The unique aspects of this patient are the atypical evolution of chromosome 21, the transformation to biphenotypic <z:hpo ids='HP_0001909'>leukemia</z:hpo>, and the occurrence of i(21q) associated with biphenotypic <z:hpo ids='HP_0001909'>leukemia</z:hpo> evolving from an <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> </plain></SENT>
</text></document>